Sutro Biopharma Overview
Sutro Biopharma Target Price
Analysts' average 12-month price target for Sutro Biopharma is $51.
Get informed when a big investor buys or sells
+ FollowShare Price
$21.3
Average Target Price
$51.00
139.4% upside
139.4% upside7 analysts in the last 4 months
High: $60 | Low: $43
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-08-07 | Stifel NicolausLaura Prendergast | $48 | 125.4% upside |  |
| 2026-06-11 | Truist Financial | $50 | 134.7% upside | |
| 2026-05-28 | BarclaysLukas Shumway | $56 | 162.9% upside | |
| 2026-05-15 | Wedbush | $60 | 181.7% upside | |
| 2026-05-15 | H.C. WainwrightAndrew Fein | $50 | 134.7% upside | |
| 2026-05-15 | Leerink Partners | $43 | 101.9% upside | |
| 2026-04-30 | Mizuho Securities | $50 | 134.7% upside | |
| 2025-03-14 | Piper Sandler | $20 |  6.1% downside | |
| 2024-10-11 | Bank of America SecuritiesTazeen Ahmad | $120 | 463.4% upside | |
| 2024-10-11 | H.C. WainwrightAndrew Fein | $120 | 463.4% upside | |
| 2024-08-16 | Truist FinancialAsthika Goonewardene | $150 | 604.2% upside | |
| 2024-05-14 | Deutsche BankJames Shin | $100 | 369.5% upside | |
| 2024-05-14 | WedbushDavid Nierengarten | $80 | 275.6% upside | |
| 2024-04-03 | OppenheimerJay Olson | $100 | 369.5% upside | |
| 2024-04-03 | Piper SandlerEdward Tenthoff | $110 | 416.4% upside | |
| 2024-04-02 | Truist FinancialAsthika Goonewardene | $180 | 745.1% upside | |
| 2023-01-13 | Truist Financial | $250 | 1073.7% upside | |
| 2023-01-10 | Piper Sandler | $180 | 745.1% upside | |
| 2022-06-28 | Piper SandlerEdward Tenthoff | $160 | 651.2% upside | |